133 related articles for article (PubMed ID: 36524812)
1. Discovery of 10
Zhan Z; Ji Y; Su H; Fang C; Peng X; Liu Q; Dai Y; Lin D; Xu Y; Ai J; Duan W
J Med Chem; 2023 Jan; 66(1):220-234. PubMed ID: 36524812
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor.
Zhang H; Peng X; Dai Y; Shao J; Ji Y; Sun Y; Liu B; Cheng X; Ai J; Duan W
J Med Chem; 2021 Apr; 64(7):3956-3975. PubMed ID: 33733758
[TBL] [Abstract][Full Text] [Related]
3. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.
Burbridge MF; Bossard CJ; Saunier C; Fejes I; Bruno A; Léonce S; Ferry G; Da Violante G; Bouzom F; Cattan V; Jacquet-Bescond A; Comoglio PM; Lockhart BP; Boutin JA; Cordi A; Ortuno JC; Pierré A; Hickman JA; Cruzalegui FH; Depil S
Mol Cancer Ther; 2013 Sep; 12(9):1749-62. PubMed ID: 23804704
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a 1,6-naphthyridin-4-one-based AXL inhibitor with improved pharmacokinetics and enhanced in vivo antitumor efficacy.
Lan Y; Peng X; Ji Y; Su Y; Duan W; Ai J; Zhang H
Eur J Med Chem; 2024 Feb; 265():116045. PubMed ID: 38128234
[TBL] [Abstract][Full Text] [Related]
5. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
Rho JK; Choi YJ; Kim SY; Kim TW; Choi EK; Yoon SJ; Park BM; Park E; Bae JH; Choi CM; Lee JC
Cancer Res; 2014 Jan; 74(1):253-62. PubMed ID: 24165158
[TBL] [Abstract][Full Text] [Related]
6. Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation.
Xu D; Sun D; Wang W; Peng X; Zhan Z; Ji Y; Shen Y; Geng M; Ai J; Duan W
Eur J Med Chem; 2021 Aug; 220():113497. PubMed ID: 33957388
[TBL] [Abstract][Full Text] [Related]
7. Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors.
Szabadkai I; Torka R; Garamvölgyi R; Baska F; Gyulavári P; Boros S; Illyés E; Choidas A; Ullrich A; Őrfi L
J Med Chem; 2018 Jul; 61(14):6277-6292. PubMed ID: 29928803
[TBL] [Abstract][Full Text] [Related]
8. Development of the phenylpyrazolo[3,4-
Lee HJ; Pham PC; Pei H; Lim B; Hyun SY; Baek B; Kim B; Kim Y; Kim MH; Kang NW; Min HY; Kim DD; Lee J; Lee HY
Theranostics; 2021; 11(4):1918-1936. PubMed ID: 33408789
[No Abstract] [Full Text] [Related]
9. HGF-induced formation of the MET-AXL-ELMO2-DOCK180 complex promotes RAC1 activation, receptor clustering, and cancer cell migration and invasion.
Li W; Xiong X; Abdalla A; Alejo S; Zhu L; Lu F; Sun H
J Biol Chem; 2018 Oct; 293(40):15397-15418. PubMed ID: 30108175
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationship study of 1,6-naphthyridinone derivatives as selective type II AXL inhibitors with potent antitumor efficacy.
Zhuo L; Guo M; Zhang S; Wu J; Wang M; Shen Y; Peng X; Wang Z; Jiang W; Huang W
Eur J Med Chem; 2024 Feb; 265():116090. PubMed ID: 38169272
[TBL] [Abstract][Full Text] [Related]
11. AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model.
Chen TJ; Mydel P; Benedyk-Machaczka M; Kamińska M; Kalucka U; Blø M; Furriol J; Gausdal G; Lorens J; Osman T; Marti HP
Physiol Rep; 2021 Dec; 9(23):e15140. PubMed ID: 34877810
[TBL] [Abstract][Full Text] [Related]
12. Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells.
Corno C; Gatti L; Lanzi C; Zaffaroni N; Colombo D; Perego P
Curr Med Chem; 2016; 23(15):1496-512. PubMed ID: 27048336
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors.
Chan S; Zhang Y; Wang J; Yu Q; Peng X; Zou J; Zhou L; Tan L; Duan Y; Zhou Y; Hur H; Ai J; Wang Z; Ren X; Zhang Z; Ding K
J Med Chem; 2022 Nov; 65(22):15374-15390. PubMed ID: 36358010
[TBL] [Abstract][Full Text] [Related]
14. Bemcentinib and Gilteritinib Inhibit Cell Growth and Impair the Endo-Lysosomal and Autophagy Systems in an AXL-Independent Manner.
Zdżalik-Bielecka D; Kozik K; Poświata A; Jastrzębski K; Jakubik M; Miączyńska M
Mol Cancer Res; 2022 Mar; 20(3):446-455. PubMed ID: 34782372
[TBL] [Abstract][Full Text] [Related]
15. 4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors.
Tan L; Zhang Z; Gao D; Luo J; Tu ZC; Li Z; Peng L; Ren X; Ding K
J Med Chem; 2016 Jul; 59(14):6807-25. PubMed ID: 27379978
[TBL] [Abstract][Full Text] [Related]
16. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B
Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476
[TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R
Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of new Axl kinase inhibitors containing 1,3,4-oxadiazole acetamide moiety as novel linker.
Xu C; Han Y; Xu S; Wang R; Yue M; Tian Y; Li X; Zhao Y; Gong P
Eur J Med Chem; 2020 Jan; 186():111867. PubMed ID: 31757525
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Landscape of AXL Receptor Kinase in Triple-Negative Breast Cancer.
Ozyurt R; Ozpolat B
Mol Cancer Ther; 2023 Jul; 22(7):818-832. PubMed ID: 37028809
[TBL] [Abstract][Full Text] [Related]
20. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.
Holland SJ; Pan A; Franci C; Hu Y; Chang B; Li W; Duan M; Torneros A; Yu J; Heckrodt TJ; Zhang J; Ding P; Apatira A; Chua J; Brandt R; Pine P; Goff D; Singh R; Payan DG; Hitoshi Y
Cancer Res; 2010 Feb; 70(4):1544-54. PubMed ID: 20145120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
